Generic Ximino Availability
Last updated on Sep 11, 2024.
Ximino is a brand name of minocycline, approved by the FDA in the following formulation(s):
XIMINO (minocycline hydrochloride - capsule, extended release;oral)
-
Manufacturer: JOURNEY
Approval date: July 11, 2012
Strength(s): EQ 45MG BASE (discontinued), EQ 67.5MG BASE (discontinued), EQ 90MG BASE (discontinued), EQ 112.5MG BASE (discontinued), EQ 135MG BASE (discontinued)
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ximino. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,541,347
Patent expiration dates:
- April 2, 2027✓
- April 2, 2027
-
Patent 7,544,373
Patent expiration dates:
- April 2, 2027✓
- April 2, 2027
-
Patent 7,790,705
Patent expiration dates:
- June 24, 2025✓
- June 24, 2025
-
Patent 7,919,483
Patent expiration dates:
- March 7, 2027✓
- March 7, 2027
-
Minocycline oral dosage forms for the treatment of acne
Patent 8,252,776
Issued: August 28, 2012
Inventor(s): Wortzman Mitchell & Plott R. Todd & Bhatia Kuljit & Patel Bhiku
Assignee(s): Medicis Pharmaceutical CorporationMinocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- June 24, 2025✓
- June 24, 2025
-
Minocycline oral dosage forms for the treatment of acne
Patent 8,268,804
Issued: September 18, 2012
Inventor(s): Wortzman Mitchell & Plott R. Todd & Bhatia Kuljit & Patel Bhiku
Assignee(s): Medicis Pharmaceutical CorporationMinocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- June 24, 2025✓
- June 24, 2025
More about Ximino (minocycline)
- Ximino consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: tetracyclines
- Breastfeeding
- En español
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.